4,700 Shares in Becton, Dickinson and Company $BDX Bought by Stonebridge Capital Management Inc.

Stonebridge Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, Holdings Channel.com reports. The firm acquired 4,700 shares of the medical instruments supplier’s stock, valued at approximately $711,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Brighton Jones LLC increased its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Becton, Dickinson and Company by 4.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after buying an additional 26,671 shares during the last quarter. Cooke & Bieler LP boosted its holdings in shares of Becton, Dickinson and Company by 27.2% during the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after buying an additional 240,673 shares during the period. Northside Capital Management LLC grew its holdings in Becton, Dickinson and Company by 18.3% in the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after buying an additional 9,494 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $2,567,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 11,704 shares of company stock worth $1,963,618. 0.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on BDX. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Royal Bank Of Canada boosted their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. Bank of America lowered their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Finally, Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $185.67.

Becton, Dickinson and Company Trading Up 0.2%

Shares of BDX opened at $190.22 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The business has a 50-day moving average of $164.35 and a 200 day moving average of $160.49. The firm has a market cap of $52.41 billion, a P/E ratio of 57.30, a price-to-earnings-growth ratio of 13.38 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.